Search Browse Earnings

Immix Biopharma, Inc. — SlamSEC

Immix Biopharma, Inc.

Nasdaq:IMMX

Pharmaceutical Preparations·LOS ANGELES, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$20.0M

+0.0% YoY

FY 2024

Adj. EBITDA

-$16.1M

-80.7% margin

FY 2024

Net Income

-$15.4M

-77.1% margin

FY 2024

EPS (Diluted)

-$0.89

FY 2024

Stock Price

$10.40

+2.7%

2026-03-10

52W Range

$1.34 – $10.71

P/E Ratio

-11.7x

Market Cap

$349.2M

Cash

$17.5M

FY 2024

Total Debt

$50,000

FY 2022

Net Cash

$17.5M

FY 2022

Enterprise Value

$331.8M

Debt / EBITDA

1.1x

FY 2024

EV / EBITDA

-20.6x

Employees

—

CEO

Rachman Ilya M

CFO

Morris Gabriel S